GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Core Viewpoint - GRI Bio, Inc. has announced a public offering of 10,666,667 shares of common stock and Series F warrants, aiming to raise approximately $8 million for product development and general corporate purposes [1][3]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through Natural Killer T (NKT) cell modulators [6]. - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [6]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [6]. Offering Details - The public offering is priced at $0.75 per share, with Series F warrants exercisable at the same price, expiring five years after issuance [1]. - The offering is expected to close around December 12, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Financial Implications - The gross proceeds from the offering are anticipated to be approximately $8 million before deducting fees and expenses [3]. - If fully exercised, the Series F warrants could provide an additional $8 million in gross proceeds [3].